ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Human Protein Index Stirs NCI, NCAB Interest, Fires Up Growing Controversy

August 7, 1981

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996

In Brief: Calabresi: Rimer: Outstanding ”For NCAB Chair; board Should Maintain Strong Leadership Role

September 23, 1994

FDA Updates Safety Information for 5-Alpha Reductase Inhibitors

June 17, 2011

BioMedicines Begins Kidney Cancer Study; EntreMed Moves Forward.

February 25, 2000

Fifty-Nine CCOP Awards Made; Payline 250, Six Funded as Exceptions

May 27, 1983